The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Sam Slezak originally set out to become a trainer for professional athletes. Here’s how and why he became a project manager for a landmark national Alzheimer’s study instead.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
Initial results in a clinical trial aimed at early-onset Alzheimer’s didn’t look promising – but upon further review, the data has spurred further study.
Major Alzheimer’s Association grant to enable researchers to test a drug that could slow the progression of Alzheimer’s disease.
With a special combination of compassionate care and scientific inquiry, she’s part of the front-line fight to end Alzheimer’s.
Aducanumab maker Biogen seeking FDA review in early 2020; if approved, it will become the first drug to remove amyloid protein from the brain and slow the progression of Alzheimer’s disease (AD).
A look inside the Memory and Aging Program at Butler Hospital and how Southern New Englanders are contributing to the mounting battle against Alzheimer’s.
The Memory and Aging Program at Butler Hospital will launch trials of two new treatments aimed at preventing Alzheimer’s in early 2020.
The Memory and Aging Program at Butler Hospital is a world-wide leader in the fight against Alzheimer's. We are dedicated to developing breakthrough treatments for Alzheimer's disease through cutting-edge research into early detection and treatment.
Our research and future breakthroughs depend on the participation of people with normal memory who may be at risk for dementia and those who are already experiencing memory loss, as well as the support of committed community partners, supporters and volunteers.
Can healthy lifestyle changes help to protect memory and thinking in aging adults who are at risk? We’re looking for people ages 60 – 79 to participate in the U.S. POINTER study to find out.
READ MORE
After spending 25 years caring for Alzheimer’s patients Dr. Daniel Gibbs developed the disease himself. He’s now been living with it for at least 13 years, and he’s on a mission to spread an important message.
READ MORE